Repetitive phosphorus-32 peritoneal instillations in a patient with malignant ascites.
During the last decade, intraperitoneal injection of phosphorus-32 chromic phosphate (P-32 CP) has been used principally for its initial intended purpose, the palliative management of malignant ascites. The authors describe a patient with a stage IIIB well-differentiated extraovarian peritoneal serous papillary adenocarcinoma. As a palliative treatment for malignant ascites, P-32 CP was instilled intraabdominally eight times. Adverse effects were limited to the third instillation, when abdominal pain occurred as a result of leakage of the P-32 CP in the subcutaneous tissue. The P-32 CP instillations reduced the frequency of paracentesis for almost 1 year, until disease progression prevented palliation. Considering the few palliative options, there could be more widespread use of P-32 CP as a palliative treatment for patients with malignant ascites caused by ovarian cancer or extraovarian peritoneal adenocarcinoma. However, intraperitoneal P-32 CP is not without potential intestinal complications, which must be considered before it is recommended.
Balink
Hans
H
Department of Nuclear Medicine, University Hospital Utrecht, The Netherlands. hbalink@azu.nl
Sijmons
Edith A
EA
Zonnenberg
Bernard A
BA
De Klerk
John M H
JM
D000231:Adenocarcinoma, Papillary / Q000150:complications / Q000532:radiotherapy; D000328:Adult; D001201:Ascites / Q000209:etiology / Q000532:radiotherapy* / Q000601:surgery; D017608:Chromium Compounds / Q000008:administration & dosage* / Q000627:therapeutic use*; D019583:Dose Fractionation, Radiation; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007274:Injections, Intraperitoneal; D010051:Ovarian Neoplasms / Q000532:radiotherapy; D010166:Palliative Care / Q000379:methods*; D019152:Paracentesis; D010534:Peritoneal Neoplasms / Q000150:complications / Q000532:radiotherapy*; D010710:Phosphates / Q000008:administration & dosage* / Q000627:therapeutic use*; D019275:Radiopharmaceuticals / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome
D017608:Chromium Compounds; D010710:Phosphates; D019275:Radiopharmaceuticals; C509369:chromic phosphate